Feb 24 – Frontier Biotechnologies said on Tuesday it has struck a deal with GSK, granting the British drugmaker worldwide rights to develop two small interfering RNA therapies targeting kidney diseases in an agreement that could be worth up to $1 billion.
(Reporting by Sri Hari N S in bengaluru; Editing by Vijay Kishore)
Comments